Printer Friendly

SOMALOGIC GETS RIGHTS TO DNA MODIFICATION PATENTS.

SomaLogic, Inc., Boulder, Colo., a privately held proteomics company, has significantly expanded its intellectual property base by acquiring an exclusive license to several key foreign and domestic patents that enable the development of aptamers with enhanced chemical diversity. These DNA modification chemistries have been integrated into the proprietary SELEX(tm) process and are expected to improve aptamer performance for virtually any protein target.

"This new DNA modification technology will make our aptamer identification program even more aggressive," stated Patricia K. Scheller, CEO of SomaLogic. "It signifies another advance in SomaLogic's efforts to expand the content of our aptamer arrays and discover protein-based disease signatures."

"By combining the advantages of established aptamer technology with more antibody-like chemical diversity, we can now address the widest possible range of protein targets," added Bruce Eaton, senior director of research at SomaLogic. "Since these technologies have already been optimized, they also provide SomaLogic with clear pathways to commercialization."

Since its founding in 1999, SomaLogic has developed aptamer arrays for multiplexed, quantitative protein measurements. SomaLogic uses these arrays in its protein signature discovery program to identify the complex relationships between proteins, diseases and health. The company is committed to commercializing novel proteomics-based diagnostics that will drive new approaches for screening, diagnosing and managing disease.

About SomaLogic

SomaLogic is developing novel proteomics systems and applications based on its proprietary aptamer technology. Aptamers are single-stranded DNA and RNA molecules that, like antibodies, can bind to target molecules with high affinity and specificity. Aptamers are identified using the proprietary SELEX process and may offer significant advantages for multiplexed protein measurements. SomaLogic is headquartered in Boulder, Colorado.

For more information, visit http://www.somalogic.com or call 303/625-2066.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Geographic Code:1USA
Date:Sep 1, 2004
Words:279
Previous Article:DYAX/GENZYME PHASE II TRIAL OF DX-88 MEETS ENDPOINT.
Next Article:HYBRIDON'S OLIGONUCLEOTIDES SHOW POTENT ADJUVANT ACTIVITY.
Topics:


Related Articles
Hybridon announces issuance of a dominant second generation antisense patent.
Hybridon obtains second generation ribozyme patent.
U.S. Genomics awarded pioneering patent.
Mobious Genomics patents ultra high speed sequencing technology.
Vical granted key DNA vaccine patent in Europe.
Lexicon extends intellectual property portfolio with patent on gene trapping.
Benitec grants ddRNAi license to Artemis for development of transgenics.
Lexicon granted exclusive license to Cellectis' homologous recombination technology.
Keeping-up intellectual property lifelines for life science ventures.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters